v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 1,038,952 $ 4,203,488
Advances on research and development contract services 78,016
Prepaid insurance 20,898 17,116
Other prepaid expenses 85,653 10,000
Total assets 1,145,503 4,308,620
Current liabilities:    
Accounts payable and accrued expenses, including $27,500 and $36,250 to related parties at December 31, 2024 and 2023, respectively 83,206 156,758
Research and development contract liabilities, including $0 and $120,768 to related parties at December 31, 2024 and 2023, respectively 235,078 157,100
Total current liabilities 318,284 313,858
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares at December 31, 2024 and 2023 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares at December 31, 2024 and 2023 225 225
Additional paid-in capital 49,394,687 48,976,265
Accumulated deficit (52,067,693) (48,481,728)
Total stockholders’ equity 827,219 3,994,762
Total liabilities and stockholders’ equity $ 1,145,503 $ 4,308,620

Source

HTML PDF
ZIP